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I. Introduction     1 
I. INTRODUCTION 
Infectious diseases are still one of the leading causes of death worldwide. 
Even if the diagnostic and therapeutic opportunities have been improved 
year by year, there are still a lot of infectious diseases completely 
untreatable. These diseases represent one of the major challenges in 
public health. For this reason the development of preventive measures 
such as vaccines is supposed to have high priority in medical research.  
Generally many different strategies for the generation of new vaccines are 
pursued. Today’s research works on live-attenuated or inactivated 
vaccines, subunit or DNA vaccines as well as on viral vector vaccines. As 
far as viral vectors are concerned, poxviruses serve as a promising 
platform for vaccine development and production. In this context Modified 
Vaccinia virus Ankara (MVA), a member of the family Poxviridae, has 
successfully been tested as a vector for various infectious antigens in 
phase I to IIb clinical trials. MVA is a highly attenuated and safety tested 
Vaccinia virus strain which can stably express high amounts of 
heterologous protein. This replication-deficient viral vector has been 
generated through more than 500 growth passages on chicken embryo 
fibroblasts. Recently published data show that MVA is able to trigger both, 
antigen-specific humoral immune response and cellular immune response. 
Especially the potent induction of antigen-specific T cells gets more and 
more into the focus of vaccine development. Enhancing this part of the 
immune reaction seems to be a promising approach in the control of 
viruses with a high antigenic shift potential such as influenza.  
The aim of this project was to improve MVA as a viral vector through 
enhancing its cellular immunogenicity. Therefore green fluorescent protein 
(GFP) was used as a model antigen in the MVA vector system. Several 
recombinant MVA-GFP candidate vaccines were constructed containing 
GFP in combination with specific localization signals. The effects of 
myristoylation and a nuclear localization signal were investigated in vitro 
and in vivo and compared to unmodified GFP. Myristoylated GFP induced 
a significantly higher level of antigen-specific CD8+ T cells compared to all 
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other GFP variants tested. Thus, myristoylation could serve as a promising 
tool to enhance the cellular immunogenicity of specific target antigens 
expressed within the MVA vector system.   
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II. LITERATURE REVIEW 
1. T cell mediated immunity against major infectious 
diseases  
1.1. T lymphocytes 
In general, the immune system is divided into two parts, the innate and the 
adaptive immune system (CHAPLIN, 2010). Although the innate immune 
system responds universally and very rapidly in case of exposure to 
infectious agents (BEUTLER, 2004), it is rather unspecific (TOPFER et al., 
2015) and without the capacity to induce immunological memory 
(WARRINGTON et al., 2011). In contrast, the activation of the adaptive 
immune system takes more time, but it allows for selective recognition of 
specific antigens (CHAPLIN, 2010). Moreover, it is able to develop 
immunological memory (ZINKERNAGEL, 2000). This allows the immune 
system to respond more strongly and faster in case of re-encounter with 
the same infectious agent (ZINKERNAGEL, 2000; SALLUSTO et al., 
2010). For this reason the development of immunological memory is the 
basis of all vaccination strategies. Generally, efficient vaccines are 
represented by a strong and stable activation of the adaptive immune 
system.  
The adaptive immune system can be further subdivided in a cellular and a 
humoral fraction. The cellular part of the adaptive immune system consists 
of T lymphocytes, whereas the humoral immune response is 
predominantly based on antibodies produced by B cells (CHAPLIN, 2010; 
JANEWAY, 2013). All blood cells originate from pluripotent hematopoietic 
stem cells in the bone marrow (WARRINGTON et al., 2011). These cells 
can either develop further to a myeloid or to a lymphoid progenitor cell. 
The myeloid progenitor cell is the origin of all cells which belong to the 
myeloid lineage, such as red blood cells, thrombocytes and different kinds 
of granulocytes (MURPHY et al., 2008). The lymphoid progenitor cell, 
however, is the precursor of B lymphocytes, T lymphocytes and natural 
killer cells (CHAPLIN, 2010; LUCKHEERAM et al., 2012). B cells mature 
II. Literature review     4 
in the bone marrow, whereas T cells are initially released to the blood and 
develop further in the thymus (GERMAIN, 2002; BEVAN, 2004). In this 
process all T cells carrying functional T cell receptors survive positive 
clonal selection, whereas cells with receptors binding self-antigens are 
eliminated during negative clonal selection to avoid autoimmune reactions 
(KLEIN et al., 2014).  After reentering the bloodstream, T cells constantly 
circulate between the blood and lymphatic tissues (GOWANS, 1996). 
These circulating mature T cells which have not yet met their specific 
antigen, are called naive T cells (MURPHY et al., 2008).  
The T cell population can be subdivided into two major groups, cells 
carrying CD8 co-receptors (CD8+ T cells) and CD4 co-receptor (CD4+ 
T cells) positive cells (GERMAIN, 2002). CD4+ T cells are mainly involved 
in the defense of extracellular bacteria and parasites (LUCKHEERAM et 
al., 2012). Furthermore they are able to secret immuno-modulatory 
cytokines which can activate and recruit other immune cells such as 
macrophages, B lymphocytes or CD8+ T cells (BEVAN, 2004). Regulatory 
T cells can partially express CD4 on their surface as well. These cells are 
involved in an important mechanism which helps to protect the organism 
from an uncontrolled T cell response or autoimmunity (LUCKHEERAM et 
al., 2012). CD8+ T cells, on the other hand, are responsible for the 
defense of intracellular pathogens such as viruses and some bacteria. 
Their main function consists of recognizing and killing virus-infected cells. 
In this context, the induction of apoptosis is the main way to eliminate 
infections (WRIGHT et al., 2004; MURPHY et al., 2008). Therefore CD8+ 
T cells synthesize and store cytotoxic proteins such as perforin or 
granzyme in granules (MURPHY et al., 2008). Perforin is able to form 
pores in the plasma membrane which are essential for the translocation of 
granzyme to the cytoplasm of infected cells (MURPHY et al., 2008).  After 
entering the cell, granzyme activates proteolytic caspase cascades which 
finally result in apoptosis (MURPHY et al., 2008). For this reason CD8+ 
T cells are also called cytotoxic T cells (MURPHY et al., 2008). 
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1.2. Function of the αβ-T cell receptor 
The major task of T cells consists of recognizing foreign antigens 
presented through the body’s own cells. Therefore all T lymphocytes carry 
about 30,000 identical antigen recognition receptors with unique antigen-
binding sites on their cell surface (MURPHY et al., 2008). These T cell 
receptors (figure 1) are heterodimeric molecules consisting of two 
glycoprotein chains (α and β) which are linked via a disulfide bond (VAN 
DER MERWE & DUSHEK, 2011). The two transmembrane chains are 
composed of a constant region (Cα; Cβ) which is anchored into the plasma 
membrane, and a variable region (Vα; Vβ), responsible for the specific 
antigen recognition (MURPHY et al., 2008). The remarkably high diversity 
of the T cell receptor which is essential for the recognition of numerous 
different pathogens, is accomplished through somatic recombination of 
several gene segment sets (GRAWUNDER et al., 1998). In addition, co-
expression of CD3 is essential for the activation of T lymphocytes 
(MURPHY et al., 2008). Generally, the formation of the T cell receptor is 
similar to the structure of immunoglobulin, but T lymphocytes are not able 
to bind intact antigen directly which is possible for immunoglobulin 
(WARRINGTON et al., 2011; JOFFRE et al., 2012). Indeed, they can only 
recognize antigens which are processed into short peptide fragments and 
bound to major histocompatibility complexes (MHC) (GOLDBERG & 
ROCK, 1992; MURPHY et al., 2008). 
MHC molecules are membrane glycoproteins, encoded in the major 
histocompatibility complex of the genome (MURPHY et al., 2008). They 
can be subdivided into two differing groups, class I and II. MHC  class I 
molecules are located on the surface of nucleated cells (WRIGHT et al., 
2004; JOFFRE et al., 2012), whereas MHC class II molecules are only 
situated on cells of the immune system (WARRINGTON et al., 2011). The 
heterodimeric MHC class I molecules (figure 1) are assembled in the 
endoplasmic reticulum and form four different domains (WRIGHT et al., 
2004). They consist of β2-microglobulin and a larger α chain which is 
subdivided into the domains α1, α2 and α3 (WRIGHT et al., 2004; 
CHAPLIN, 2010). In this context, subunit α3 is responsible for the 
membrane anchoring, whereas α1 and α2 in combination generate the 
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peptide binding site (MURPHY et al., 2008). MHC class II molecules 
(figure 1) also include two chains, α and β, but both are anchored to the 
cell membrane and the α-chain differs from the α-subunit in MHC class I 
molecules (CHAPLIN, 2010). The two chains are subdivided into α1, α2 
and β1, β2 domains, in such a way that α1 and β1 build the peptide-binding 
cleft (MURPHY et al., 2008). Antigen fragments bound on MHC I are 
mainly recognized by CD8+ T cells (BEVAN, 2004), whereas complexes 
consisting of peptide fragments and MHC II are preferentially identified by 
CD4+ T cells (MURPHY et al., 2008).  
 
 
 
 
 
 
 
Figure 1: Structure of T cell receptor, MHC class I molecule and MHC 
class II molecule (MURPHY et al., 2008; modified)  
 
1.3. Activation of naive T cells 
Priming of naive T cells is triggered through their specific interaction with 
antigen-presenting cells (MURPHY et al., 2008; JOFFRE et al., 2012). In 
this context T cells bind to an antigenic peptide which is presented via 
MHC molecules and specifically fits to the T cell receptor. Apart from the 
interaction of the T cell receptor with the MHC complex additional signals 
are required to induce the clonal expansion of antigen-specific T cells, 
such as co-stimulatory molecules or cytokines produced by antigen-
presenting cells (MURPHY et al., 2008).  
The ligand presented on MHC molecules originates from extracellular 
pathogens or from intracellular ones. Extracellular microbes usually carry 
repetitive molecular structures consisting of lipopolysaccharides or 
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carbohydrates on their bacterial cell wall, which are known as pathogen-
associated molecular patterns (PAMPs) (JANEWAY, 1989; IWASAKI & 
MEDZHITOV, 2015). Macrophages, dendritic cells or other cells of the 
innate immune system hold pattern recognition receptors (PRR) on their 
cell surface which are able to recognize the PAMPs (JANEWAY, 1989; 
IWASAKI & MEDZHITOV, 2015). The phagocytic cells furthermore 
express receptors for the interaction with complement proteins. Apart from 
direct binding, this additionally allows for recognition of opsonized 
pathogens. After recognition and phagocytosis, antigen-presenting cells 
process the pathogen intracellularly and present the newly formed 
antigenic peptides via MHC class II on their cell surface to CD4+ T cells 
(CHAPLIN, 2010). Antigen binding and processing furthermore also 
induce enhanced cytokine production through the phagocytic cell. This 
leads to the further activation of the innate immune response as well as 
the adaptive one. Thus, antigen presenting cells, especially dendritic cells, 
serve as a link between the innate and the adaptive immune system 
(WARRINGTON et al., 2011). Intracellular pathogens like viruses or some 
bacteria usually activate the immune system through another pathway. 
Here, intracellularly produced antigenic proteins are degraded in the 
proteasome and presented on MHC class I molecules. This leads to the 
activation of CD8+ T cells (MURPHY et al., 2008).  
Apart from the two major pathways described above there are also other 
ways of antigen processing such as cross-presentation (CHAPLIN, 2010). 
This pathway plays a key role for the activation of dendritic cells by viral 
infections which do not directly affect the dendritic cells. Here, antigen-
presenting cells receive antigen delivered by other infected cells via 
phagocytosis. This is mainly carried out by dendritic cells (CRESSWELL et 
al., 2005). Afterwards the exogenous antigen can also be processed via 
the proteasome and can finally be presented to cytotoxic T cells via MHC 
class I molecules (MURPHY et al., 2008; JOFFRE et al., 2012). Generally 
this strategy helps to control viruses which are able to avoid antigen 
processing through the endogenous pathway (CHAPLIN, 2010). 
After initial priming T lymphocytes start to proliferate and differentiate into 
effector cells (AHMED & GRAY, 1996). In addition to the maturation of 
II. Literature review     8 
effector T cells, priming leads to the development of a small fraction of 
memory T cells. These are long-lived T cells (AHMED & GRAY, 1996) 
which accelerate the immune response in case of a subsequent infection 
with the same pathogen responsible for priming. Furthermore memory 
cells also exist despite the absence of their specific pathogenic antigens 
(MURPHY et al., 2008). Generally, efficient vaccines should provide both, 
T cell effector cells as well as memory T cells. This allows efficient control 
of infectious pathogens including a higher magnitude of the secondary 
response compared to primary responses (MURPHY et al., 2008; 
SALLUSTO et al., 2010).  
1.4. T cell response induced by vaccination 
Up to date vaccines represent the most effective and cost-efficient 
preventive method in modern medicine (SALLUSTO et al., 2010; 
PULENDRAN & AHMED, 2011). The comprehensive use of vaccines is 
able to protect individuals from infectious diseases and can at best even 
result in the elimination of single pathogenic organisms (SALLUSTO et al., 
2010). For decades the development of vaccines has predominantly been 
based on the induction of strong humoral immune responses. For this 
reason it is quite common that most of the vaccines currently available are 
based on the induction of antigen-specific antibodies (PLOTKIN, 2008). 
However, antibody inducing vaccines are not effective enough against 
numerous infectious pathogens which are more complex or even able to 
chance their antigenic structure, such as human immunodeficiency virus 
(HIV), influenza or Mycobacterium tuberculosis. The development of 
vaccines against HIV for example has so far not been successful 
(PULENDRAN & AHMED, 2011). 
These findings clearly demonstrate the need for novel innovative 
strategies in vaccine development. Moreover, data recently published also 
highlight the importance of the T cell response and confirm that protection 
against many threatening infectious diseases could be improved through 
an increased induction of the cellular immune system (KREMER et al., 
2012a; ALTENBURG et al., 2014). The importance of the T cell response 
is now generally accepted and therefore vaccine development is more and 
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more focusing on the induction of T cells. The requirement of a strong 
T cell response is for example clearly indicated in the control of 
tuberculosis (HOFT, 2008) or HIV (PANTALEO & KOUP, 2004). 
Additionally, influenza is also believed to require an efficient cellular 
immune response. Here, the influenza-specific T cell response even 
seems to correlate inversely with the risk of elderly people developing 
sickness following vaccination (McELHANEY et al., 2006). Furthermore, it 
is known that the protection against some infectious diseases such as 
smallpox depends on T cell memory. In fact, antibodies can prevent 
infection with smallpox and usually protect against severe disease, but the 
infection will only be asymptomatic through the help of the cellular immune 
response (PLOTKIN, 2008).  
2. Modified Vaccinia virus Ankara (MVA) as vector 
vaccine 
2.1. MVA: a member of the family Poxviridae 
Modified Vaccinia virus Ankara (MVA) is assigned to the genus 
Orthopoxvirus which belongs to the family Poxviridae (MAYR et al., 1975). 
Poxviruses (figure 2) typically hold a single linear double-stranded DNA 
genome of about 130 to 300 kilo base pairs which encodes a multiplicity of 
viral proteins (MOSS, 1996).  The virions of poxviruses are larger than 
most other animal viruses and can even be seen in light microscopy (200 
nm - 400 nm). Basically, the structure of the enveloped virions is relatively 
complex. Additionally to the biconcave core, poxviruses form two lateral 
bodies. The core includes the nucleocapsid with the s-shaped viral 
genome and DNA associated proteins (MOSS, 2013). 
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Figure 2: Structure of poxvirus virions  
(Source: ViralZone; www.expasy.org/viralzone, SIB Swiss Institute of 
Bioinformatics; with permission) 
 
The life cycle of poxviruses includes several steps which finally lead to the 
release of newly formed infectious virions (figure 3). After attachment and 
fusion with the plasma membrane, the core of the virions including the 
DNA is released to the cytoplasm of the host cell (MOSS, 2013). Early 
genes which are essential for DNA replication, transcription and translation 
of intermediate genes, are immediately transcribed (MOSS, 1996). In the 
next step uncoating takes place and DNA replication starts (McFADDEN, 
2005). Poxviruses themselves encode all enzymes and factors which are 
essential for the replication. This is remarkable because it allows 
replication in the cytoplasm independently from the host cell (MOSS, 
1996). Replication restricted to the cytoplasm furthermore prevents viral 
DNA from integrating into the host cell genome. In contrast, other DNA 
viruses usually need the cellular replication system and are partly able to 
integrate their genome into the DNA of the host cell (MOSS, 1996). In the 
further course of the life cycle, intermediate as well as late genes are 
successively transcribed (McFADDEN, 2005). Amongst other things the 
products of intermediate genes are essential for the initiation of the late 
gene transcription. In contrast, late genes encode mainly structural 
proteins which are necessary for the formation of infectious virions 
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(MOSS, 2013). Generally, this type of genetic programming is known as a 
cascade mechanism because the products of each stage regulate the 
next. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Life cycle of poxviruses 
(Source: ViralZone; www.expasy.org/viralzone, SIB Swiss Institute of 
Bioinformatics; with permission) 
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After assembly and packaging of the newly replicated DNA, the viral 
particles mature to infectious intracellular virions (mature virion, MV) and 
get wrapped in the trans-Golgi (HILLER & WEBER, 1985; SCHMELZ et 
al., 1994). The wrapped virions are directly transported to the plasma 
membrane (STOKES, 1976). Finally, the virions are released to the 
extracellular space as enveloped virions (EV)  through fusion with the cell 
membrane (MOSS, 2013).  
2.2. Origin of MVA 
The World Health Organization’s (WHO) smallpox eradication program 
finally resulted in the elimination of smallpox in 1980. Vaccinia virus, the 
virus used as vaccine during the program, was immunogenic, but it partly 
induced severe side effects (KENNEDY et al., 2009; GILBERT, 2013). 
Thus, it naturally was not the best vaccine possible, above all for people 
with immunodeficiency. For this reason, the development of safe and 
efficient smallpox vaccines was urgently needed. In this context, MVA was 
developed at the LMU Institute for Microbiology and Infectious Diseases of 
Animals in Munich (MAYR & MUNZ, 1964). It was derived from Vaccinia 
virus strain Ankara after 516 serial passages on chicken embryo 
fibroblasts (MAYR et al., 1975). This resulted among other things in six 
major deletions of DNA, including several structural proteins, host range 
genes (MEYER et al., 1991) and immune evasion genes (ANTOINE et al., 
1998). Apart from the six major deletions the genome was furthermore 
affected by a couple of point mutations, shorter deletions and insertions 
(ANTOINE et al., 1998; MEISINGER-HENSCHEL et al., 2007). Overall, 
the loss of genomic original material amounts to approximately 15% 
(about 30,000 base pairs) in comparison to the genome of the parenteral 
Chorioallantois Vaccinia virus Ankara (CVA) (MEYER et al., 1991). Thus, 
MVA lost the bigger part of its growth capacity and became replication 
deficient in mammalian cells including human cells (MAYR et al., 1975; 
CARROLL & MOSS, 1997; DREXLER et al., 1998). For this reason MVA 
can even be used as a safe vaccine for immunocompromised people, 
such as cancer patients receiving chemotherapy or people who have 
contracted immunodeficiency virus. This finding basically resulted in the 
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preferred use of MVA in vaccine development compared to the replication 
competent Vaccinia virus. But despite the inability of MVA to replicate 
early, intermediate as well as late gene expression still occurs in 
mammalian cells (SUTTER & MOSS, 1992). In general, the high-level 
attenuation of the virus allows handling of MVA in Germany under 
biosafety level 1 conditions (ZKBS, 1997) and safe application in animal 
experiments as well as in human clinical trials.  
Originally, non-recombinant MVA was used for the vaccination of more 
than 120,000 people in Germany (STICKL et al., 1974; MAYR et al., 
1978). During that period of time many field studies investigated and 
confirmed the excellent safety profile of MVA (STICKL et al., 1974; MAYR 
et al., 1975; MAYR et al., 1978). Today, MVA is approved in the European 
Union and Canada as a smallpox vaccine for active immunization, even 
for immunocompromised people (VOLLMAR et al., 2006; KENNEDY & 
GREENBERG, 2009). 
2.3. MVA: a vector for foreign genes 
 
After the eradication of human smallpox, MVA has been used as a safe 
viral vector for the generation of candidate vaccines for the prevention of 
infectious diseases and cancer. In general, MVA has several useful 
characteristics which make it suitable as a viral vector for vaccine 
development (DREXLER et al., 2004; COTTINGHAM & CARROLL, 2013; 
GILBERT, 2013; KREIJTZ et al., 2013; VOLZ & SUTTER, 2013; 
ALTENBURG et al., 2014): i) The genome of MVA shows a high plasticity 
and is relatively large which allows the insertion of foreign gene 
sequences. ii) MVA is replication deficient in mammalian cells which 
indicates the use even in immunocompromised people. iii)  Several 
studies showed an excellent safety record of MVA after use as a vaccine 
in humans. iv) MVA is able to induce humoral as well as cellular immune 
responses. v) Commonly available laboratory protocols allow easy and 
efficient handling of MVA.  
As a representative of poxviruses MVA shows a high genetic plasticity 
which enables the insertion of heterologous gene sequences. The 
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generation of recombinant MVA usually proceeds according to a well-
established and standardized laboratory system using a vector plasmid 
(KREMER et al., 2012b). Thus, foreign genes can be inserted into the viral 
genome via homologous recombination between flanking sequences in 
the vector and the MVA genome (MOSS, 1996). Besides the gene of 
interest, the vector plasmid also needs to include a promoter sequence. 
The promoter has to be Vaccinia virus specific because poxviruses avoid 
using the transcriptional system of the host cell through holding their 
complete own transcription machinery (MOSS, 1996). Furthermore the 
vector plasmid should also contain a marker gene which facilitates specific 
selection of recombinant MVA. Screening for the expression of fluorescent 
marker genes allows efficient isolation of recombinant viruses through 
several plaque passages in the cell culture. Finally, recombinant MVAs are 
able to synthesize high amounts of viral as well as recombinant protein in 
the cytosol of infected cells. This provides the basis for the function of a 
well-working expression vector (SUTTER & MOSS, 1992).  
2.4. MVA as a platform for vaccine development 
Preclinical studies already showed the suitability of MVA as a viral vector 
more than 15 years ago (MOSS et al., 1996). So far, many different 
recombinant MVAs delivering antigens of various infectious diseases have 
been constructed and characterized. Previously published data for 
example indicate the use of recombinant MVA for the prophylaxis of 
malaria or human immunodeficiency virus (COSMA et al., 2003; 
MOORTHY et al., 2003b; MOORTHY et al., 2003a). Several recombinant 
MVAs have already been tested in phase I to phase IIb clinical trials 
including vaccines against viral infections (table 1a) such as influenza, 
hepatitis or human deficiency virus (HIV) and also against bacteria and 
parasites (table 1b) (KREIJTZ et al., 2013). Vaccination with these 
recombinant MVAs has generally been well-tolerated. Safety data from 
these clinical trials have reported no severe or serious side effects 
(MOORTHY et al., 2003b; GILBERT, 2013; GOMEZ et al., 2013). 
Moreover, the MVA candidate vaccines were immunogenic as predicted in 
previous preclinical studies, and they induced humoral as well as cellular 
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immune responses (GILBERT, 2013). For this reason MVA serves as a 
promising platform for future development of efficient and safe vaccines. 
 
Table 1a: Clinical trials of recombinant MVA vaccines targeting 
viruses (KREIJTZ et al., 2013; modified) 
 
 
Target 
disease 
 
Antigen 
 
Phase  
 
Immunogenic 
 
Safe 
 
References 
 
AIDS 
 
HIV-1 Nef 
 
 
HIV-1 Env  
HIV-A gag/pol 
 
 
 
HIV-B 
Env/gag/pol/nef 
 
 
I/II 
 
 
I/II 
 
 
 
 
I/II 
 
yes 
 
 
yes 
 
 
 
 
yes 
 
yes 
 
 
yes 
 
 
 
 
yes 
 
(COSMA et al., 
2003) 
 
(BAKARI et al., 
2011) 
(MUNSERI et al., 
2015) 
 
(GOMEZ et al., 
2011)  
(GARCIA et al., 
2011) 
(GOMEZ et al., 
2015) 
 
Hepatitis 
B 
 
HBV S 
 
I 
 
yes 
 
yes 
 
(CAVENAUGH et 
al., 2011) 
 
Influenza 
 
NP and M1 
 
 
 
 
 
 
HA 
 
I/II 
 
 
 
 
 
 
I/IIa 
 
yes 
 
 
 
 
 
 
yes 
 
yes 
 
 
 
 
 
 
yes 
 
 
 
(BERTHOUD et al., 
2011)  
(LILLIE et al., 
2012)  
(ANTROBUS et al., 
2012) 
 
(KREIJTZ et al., 
2014) 
(DE VRIES et al., 
2015) 
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Table 1b: Clinical trials of recombinant MVA vaccines targeting 
bacteria and parasites (KREIJTZ et al., 2013; modified) 
 
 
Target 
disease 
 
Antigen 
 
Phase  
 
Immunogenic 
 
Safe 
 
References 
 
Malaria 
 
P. falcip. 
AMA1 
 
P.falcip. ME-
TRAP 
 
 
 
P. falcip. 
ME-TRAP 
 
P. falcip. 
ME-TRAP 
 
I 
 
 
IIb 
 
 
 
 
IIb 
 
 
I 
 
yes 
 
 
yes 
 
 
 
 
yes 
 
 
yes 
 
yes 
 
 
yes 
 
 
 
 
yes 
 
 
yes 
 
(SHEEHY et al., 
2012) 
 
(BEJON et al., 
2006) 
(BEJON et al., 
2007) 
 
(MOORTHY et al., 
2004) 
 
(HODGSON et al., 
2015) 
 
Tuberculosis 
 
85A (MTB) 
 
 
85A (MTB) 
 
IIb 
 
 
I 
 
yes 
 
 
yes 
 
yes 
 
 
yes 
 
(TAMERIS et al., 
2013) 
 
(SHEEHAN et al., 
2015) 
 
Besides the advanced investigation of promising antigens in clinical trials, 
preclinical studies consistently investigate new MVA vaccine candidates. 
In this context, recently published data for example highlight the suitability 
of MVA as a vector for more complex diseases such as Middle East 
respiratory syndrome coronavirus (MERS-CoV) (SONG et al., 2013). 
2.5. MVA’s antigen presentation pathway 
Generally, thorough knowledge of MVA’s life cycle and its antigen 
presentation pathway is essential for the development of new effective 
vaccine candidates.  In this context, the main mechanism of processing 
intracellular viral antigens delivered by MVA, is the endogenous pathway 
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(figure 4) for MHC I presented antigens (TSCHARKE et al., 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Endogenous antigen presentation in MVA infected antigen-
presenting cells (MURPHY et al., 2008; MOSS, 2013; modified)  
 
Proteases process viral proteins in the proteasome to small peptide 
fragments which are immediately transported into the endoplasmic 
reticulum (GOLDBERG & ROCK, 1992). The required length of the 
peptides for complexation with MHC I molecules is 8-10 amino acids 
(WRIGHT et al., 2004; CRESSWELL et al., 2005). The ATP-dependent 
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transport of the peptides across the endoplasmic membrane is mediated 
by two proteins called TAP 1, TAP 2 (transporters associated with antigen 
processing) which build a heterodimer (ANDROLEWICZ et al., 1993; 
CRESSWELL et al., 2005). This transport system belongs to the ATP-
binding cassette family (ABC) and consists of four domains, two 
transmembrane and two ATP-binding domains (HIGGINS, 1992). The 
encoding sequences of TAP 1 and TAP 2 are located within the MHC. It is 
remarkable that the transcription and translation of these genes can be 
enhanced by interferons which are produced by various cells of the 
immune systems as a response to viral infections (MURPHY et al., 2008). 
In the endoplasmic reticulum the viral peptide fragments are loaded on the 
MHC class I molecules (CHAPLIN, 2010). This complex is subsequently 
transported to the cell surface and presented to cytotoxic T cells 
(MURPHY et al., 2008). Generally, this strategy allows the immune system 
to detect transformed cells as well as infected cells (JOFFRE et al., 2012).  
Apart from the endogenous pathway, MVA is also able to activate 
cytotoxic T cells via cross-presentation by dendritic cells (TSCHARKE et 
al., 2015). 
3. Target antigens for MVA-induced CD8+ T cells  
3.1. Influenza antigens 
Influenza viruses cause infections in the respiratory system of humans as 
well as of animals. They show a high genetic variability and an enormous 
capacity for antigenic drift (HAMPSON & MACKENZIE, 2006; GAMBLIN & 
SKEHEL, 2010) which can lead to the development of new viral subtypes. 
This strategy allows the virus to evade the humoral immunity of the host 
(WONG & PAMER, 2003). For this reason novel influenza subtypes 
especially possess pandemic potential because they often cannot be 
recognized and eliminated by antibodies induced by vaccination with the 
seasonal influenza vaccine or by a previous infection (HILLAIRE et al., 
2011). Here, the virus-specific cellular immune response is considered to 
play a key role in the control of the virus and could also strongly support 
the induction of cross-protective immunity (HILLAIRE et al., 2011; 
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ALTENBURG et al., 2014). Different studies have already shown the 
relevance of CD8+ T cell responses in challenge experiments (FLYNN et 
al., 1998; WONG & PAMER, 2003). Furthermore, it is known that memory 
T cells are essential for rapid protection of mice in case of reinfection 
(FLYNN et al., 1999; WONG & PAMER, 2003). Therefore the strong 
activation of T cells is a vital target in today’s development of more broad-
protective vaccines. Successful development and licensing of such 
vaccines is a major aim regarding the high morbidity and mortality of 
epidemic influenza outbreaks which are especially threatening for elderly 
or immunocompromised people.  
In 1994 a study first described that vaccination with recombinant MVA 
expressing hemagglutinin (HA) and nucleoprotein (NP) is able to protect 
mice from lethal challenge with influenza virus (SUTTER et al., 1994). 
Today several influenza antigens are known and investigated for their 
potential to induce T cell responses. Recently published data evaluated 
different MVA vaccines encoding influenza antigens for their potential to 
induce antigen-specific CD8+ T cell responses. In this context, 
hemagglutinin, nucleoprotein and matrixprotein 1 (M1) are promising 
antigens used in the MVA vector system. Hemagglutinin is a glycoprotein 
located on the surface of influenza virions (GAMBLIN & SKEHEL, 2010). It 
mediates binding of the virus particle to the host cell and is also involved 
into the fusion of the viral envelope with the endosome membrane 
(GARTEN & KLENK, 1999). In contrast, nucleoprotein and matrixprotein 
belong to the structural proteins of the virus. Nucleoprotein is known as an 
RNA-binding protein which is responsible for the encapsidation of viral 
RNA (PORTELA & DIGARD, 2002). Thus, it also interacts with 
matrixprotein 1 and other viral molecules. It furthermore includes a nuclear 
localization signal and mediates the translocation of viral RNA into the cell 
nucleus. M1 is also a RNA-binding protein (YE et al., 1999), but it is able 
to bind the plasma membrane as well. Simultaneous binding of RNA and 
membrane through M1 is important for the encapsidation of the RNA into 
the viral envelope. Table 2 shows a selection of recombinant MVA recently 
tested expressing influenza proteins. It summarizes their potential to 
induce cellular immune responses against homologous and heterologous 
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influenza subtypes.  
 
Table 2: Influenza antigens and their potential to induce antigen-
specific CD8+ T cell responses  
 
 
Influenza 
 virus 
 
Antigen 
 
Induction of 
antigen-specific 
CD8+ T cells 
 
Protective in 
influenza 
challenge 
 
References 
 
H1N1 
 
HA+NP 
 
yes 
 
yes 
 
 
(SUTTER et 
al., 1994) 
 
H5N1 
 
NP 
 
yes 
 
yes (H5N1, 
H7N1, H9N2) 
 
(HESSEL et 
al., 2014) 
 
H3N2 
 
NP+M1 
 
yes 
 
yes 
 
 
(BERTHOUD 
et al., 2011) 
 
H1N1+H5N1 
 
HA (H1N1) 
+ NP (H5N1) 
 
yes 
 
yes (H1N1, 
H5N1), partial 
protection 
(H3N2) 
 
(BREWOO et 
al., 2013) 
 
3.2. Model antigens  
 
Experimental studies are consistently testing antigens of various infectious 
diseases delivered by MVA for their potential to induce strong T cell 
responses. Here, it is also worthwhile to carefully study modification tools 
for the promising antigens experimentally pre-selected. Many different 
modification tools are considered because of their capacity to enhance the 
immunogenicity of antigens such as localizing target antigens to 
subcellular compartments, co-expression of different immunogenic 
molecules or the use of different promoters (GASTEIGER et al., 2007). In 
this context model antigens play a key role because they allow to test the 
potency of antigenic modification tools independently of specific antigens. 
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In the next step the combination of the most promising tools and pre-
selected antigens can be investigated for their immunogenicity. This 
procedure clearly decreases the number of experiments and studies which 
would usually be necessary to test all combinations of modifications and 
antigens. Several model antigens with different characteristics are 
established for the MVA vector system. Consequently the most commonly 
used model systems are to be presented in the following chapter.  
3.2.1. Ovalbumin 
The chicken egg white protein ovalbumin (OVA) belongs to the serpin 
superfamily (HUNT & DAYHOFF, 1980). The name of this superfamily is 
based on the function of the main part of all associated proteins which 
typically are serin proteinase inhibitors (GETTINS, 2002). The exact 
function of the non-inhibitory OVA is still unknown, but it is supposed to be 
a storage protein (GETTINS, 2002; BENARAFA & REMOLD-O'DONNELL, 
2005). OVA’s X-ray structure was finally determined in 1990 (STEIN et al., 
1990). This well-conserved protein has so far been used as a model 
antigen for recombinant MVA in many different experimental studies. Cells 
infected with recombinant MVA expressing OVA (MVA-OVA) usually 
secret ovalbumin constantly to the medium (BECKER et al., 2014). For 
this reason OVA serves as an appropriate model antigen for the 
comparison of modification tools which are supposed to have an influence 
on the strength of the antigen expression such as different promoters 
(BECKER et al., 2014). Furthermore, secretion to the medium allows 
analysis of protein expressed without affecting the cells. OVA is also well-
established and frequently used as a model antigen for the analysis and 
comparison of T cell responses in immunization experiments (BAUR et al., 
2010; BECKER et al., 2014). It is not only used as a model system, but 
also as a promising antigen in the development of vaccines for the 
prevention of allergic symptoms caused by food allergies. Thus, previously 
published data clearly suggest MVA-OVA as a potential vaccine against 
allergic symptoms induced by chicken egg white (ALBRECHT et al., 2008; 
BOHNEN et al., 2013).  
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3.2.2. β-Galactosidase 
β-Galactosidase is a member of the enzyme family glycosyl hydrolases 
which are typically able to hydrolase O-glycosyl linkages (HENRISSAT, 
1991). For this reason these enzymes play a key role in the carbohydrate 
metabolism of the human body. Enzyme deficiencies triggered through 
mutations in the β-Galactosidase gene can result in GM1-gangliosidosis or 
Morquio B syndrome. Both are rare autosomal recessive lysosomal 
storage diseases (CACIOTTI et al., 2011). GM1-gangliosidosis results in a 
pathological accumulation of acidic lipids in the lysosomes, especially in 
cells of the central nerve system. In contrast, Morquio B syndrome is a 
mucopolysaccharidosis which mainly affects the skeletal and the 
cardiovascular system (CACIOTTI et al., 2011). The β-Galactosidase used 
in molecular biology is originated from E. coli and is encoded by the lacZ 
gene. This gene belongs to the inducible lac operon system (OSBOURN & 
FIELD, 2009). It helps the bacteria to permanently adapt their enzyme 
expression to the availability of alimentary substrate. In the presence of 
lactose and in the simultaneous absence of glucose, the lac operon 
system is activated and encodes - apart from other molecules - β-
Galactosidase which is essential for the lactose metabolism. β-
Galactosidase catalyzes the hydrolysis of the disaccharide lactose in 
glucose and  galactose (LEONARD et al., 2015). In molecular biology β-
Galactosidase serves on the one hand as a reporter for gene expression 
because it is able to stain tissue cultures blue in the presence of enzyme 
specific substrate (ARMIT, 2015). On the other hand it is also used as a 
viral tumor associated antigen in cancer research. These antigens allow 
the generation of recombinant anti-cancer vaccines on the basis of MVA. 
Furthermore, β-Galactosidase delivered by MVA is able to specifically 
induce T lymphocytes (CARROLL et al., 1997).  For this reason research 
especially makes use of recombinant MVA delivering β-Galactosidase in 
studies about novel treatment options against cancer, in which cytotoxic 
T cells play the key role (CARROLL et al., 1997). T cell leucemias induced 
by T cell lymphotropic virus (DE THE et al., 1994) or Burkitt’s lymphoma 
caused by Epstein-Barr virus (MOSS et al., 1994) for example belong to 
this kind of cancer. More than 15 years ago MVA expressing β-
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Galactosidase has also successfully been used to protect and treat 
pulmonary metastases which deliver β-Galactosidase (CARROLL et al., 
1997).  
3.2.3. Green fluorescent protein (GFP) 
In general, fluorescent proteins serve as an innovate tool in molecular 
biology. They allow the visualization, observation and thus the better 
understanding of processes within cells, bacteria or viruses. Today many 
different fluorescent proteins are established for laboratory use such as 
mCherry (red fluorescent protein), mOrange (orange fluorescent protein) 
or Venus (yellow fluorescent protein) (KREMERS et al., 2011).  But the 
discovery of green fluorescent protein and its use in cell culture is still 
considered as the milestone in the development of fluorescent proteins. 
GFP was derived from the green fluorescent jellyfish Aequorea victoria 
and firstly described in 1962 (SHIMOMURA et al., 1962). The crystal 
structure of GFP was finally published in 1996 (YANG et al., 1996). 
Generally, the field of fluorescent proteins has been studied very well over 
years. In 2008 the Nobel Prize in chemistry was finally awarded to Martin 
Chalfie, Osamu Shimomura and Roger Tsien for their outstanding 
scientific studies about GFP (CHALFIE, 2009; REMINGTON, 2011). As 
early as in 1994 Chalfie published the suitability of GFP as a marker for 
gene expression in prokaryotic as well as in eukaryotic cells. It is 
remarkable that the expression of GFP has no obvious negative influence 
on cell growth or function which allows monitoring of gene expression and 
protein localization in living cells (CHALFIE et al., 1994). Moreover, the 
fluorescence is not affected by treatment with formaldehyde which is 
useful for the analysis of fixed cell preparations (CHALFIE et al., 1994).  
By now GFP has been established in many experimental settings. It is 
very well characterized and probably the most commonly used fluorescent 
protein in molecular biology. GFP is a protein of approximately 240 amino 
acids which can spontaneously absorb blue light (maximum at 395 nm). 
Furthermore it is able to very stably emit green fluorescence (peak at 
309 nm) (CHALFIE et al., 1994). GFP can efficiently be targeted to the 
major cell organelles as for example the cell nucleus, plasma membrane, 
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endoplasmic reticulum or mitochondria (TSIEN, 1998). So far GFP has 
also been used as a visualizable tool in many studies dealing with 
recombinant MVA (for example: COSMA et al., 2004; PASCUTTI et al., 
2011; WONG et al., 2011) including the analysis of T cell responses (DI 
PILATO et al., 2015). 
In this study we used GFP as a model antigen to analyze the influence of 
localization signals on the induction of antigen-specific cellular 
immunogenicity. We preferred working with GFP as a model antigen 
because it has several characteristics which are beneficial for the 
experimental setting: i) GFP is - in difference to OVA - not secreted to the 
medium which could influence and disturb the experimental testing 
systems. ii) GFP allows direct visualization of the different subcellular 
protein localization sites. iii) GFP as a model antigen allows to analyze the 
effect triggered by localization signals independently of specific infectious 
antigens. iv) GFP is very well characterized and established in many 
experimental settings. v) GFP has already successfully been used in the 
MVA vector system. 
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III. OBJECTIVES 
Due to the need of new efficient and safe vaccines for the control of 
complex infectious diseases and due to the suitability of MVA as an 
effective and safe viral vector this work describes: 
(i) The generation of recombinant MVA expressing GFP in combination 
      with different localization signals 
(ii) In vitro characterization of the recombinant MVA 
 Analysis on DNA level 
 Analysis on protein level 
 Fluorescence microscopy 
(iii) In vivo characterization of the recombinant MVA 
 Vaccination experiment in mice 
 Analysis of the induced CD8+ T cell response 
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IV. RESULTS 
The manuscript is presented in form accepted for publication (MARR et 
al., 2016).  
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Activation of CD8+ T cells is an essential part of immune responses 
elicited by recombinant Modified Vaccinia virus Ankara (MVA). 
Strategies to enhance T cell responses to antigens may be 
particularly necessary for broadly protective immunization against 
influenza A virus infections or for candidate vaccines targeting 
chronic infections and cancer. Here, we tested recombinant MVAs 
that target a model antigen, green fluorescent protein (GFP), to 
different localizations in infected cells. In vitro characterization 
demonstrated that GFP accumulated in the nucleus (MVA-nls-GFP), 
associated with cellular membranes (MVA-myr-GFP) or was equally 
distributed throughout the cell (MVA-GFP). On vaccination, we found 
significantly higher levels of GFP-specific CD8+ T cells in MVA-myr-
GFP vaccinated BALB/c mice than in those immunized with MVA-
GFP or MVA-nls-GFP. Thus, myristoyl modification may be a useful 
strategy to enhance CD8+ T cell responses to MVA-delivered target 
antigens.  
Modified Vaccinia virus Ankara (MVA) is a replication-deficient and safety-
tested Vaccinia virus strain that can be engineered as a vector virus 
encoding foreign antigens (SUTTER & MOSS, 1992; SUTTER et al., 
1994). Today, MVA vectors serve as an established platform technology 
for developing vaccines against infectious diseases and cancer (KREIJTZ 
et al., 2013; VOLZ & SUTTER, 2013; ALTENBURG et al., 2014; 
SEBASTIAN & GILBERT, 2016). Various recombinant MVA have been 
tested successfully in phase I to phase IIb clinical trials, and have been 
found to be safe and immunogenic, inducing both target antigen-specific 
antibodies and cellular immune responses (GILBERT, 2013; GOMEZ et 
al., 2013). In a recent phase I study, immunizations with recombinant MVA 
delivering the hemagglutinin (HA) antigen of Influenza A virus H5N1 
(MVA-HA) induced high levels of H5-specific antibodies (KREIJTZ et al., 
2014).  
In addition, the ability to activate strong cellular immune responses is an 
important factor for the use of recombinant MVA in the search for influenza 
vaccines with improved efficacy. Enhancing antigen specific T cell 
responses might be a promising strategy for developing broadly protective 
IV. Results     28 
vaccines against influenza A virus. So far, two major parameters are 
reported to influence efficient T cell responses: (i) optimal use of early 
promoters for recombinant gene expression to support direct antigen 
presentation and priming of T cells (BRONTE et al., 1997; 
KASTENMULLER et al., 2006; KASTENMULLER et al., 2007) and (ii) the 
synthesis and delivery of stable mature protein antigens as preferred 
substrates for efficient priming of T cells by cross-presentation 
(GASTEIGER et al., 2007; PASCUTTI et al., 2011).  
 
Localizing target antigens to subcellular compartments is also considered 
as an innovative approach to enhance the cellular immune response 
(GASTEIGER et al., 2007). To analyze the effect of different antigen 
localizations on immunogenicity, we chose green fluorescent protein 
(GFP) as a model antigen and assessed the induction of GFP epitope-
specific CD8+ T cells mediated by recombinant MVA producing either 
unmodified GFP or GFPs containing nuclear localization (nls) or 
myristoylation (myr) signals. The gene sequences encoding the target 
antigens GFP, myr-GFP and nls-GFP were introduced at the site between 
the Vaccinia virus (VACV) G1L and I8R genes (all gene nomenclatures as 
established for VACV strain Copenhagen; GOEBEL et al., 1990) by 
homologous recombination and placed under transcriptional control of 
Pvgf promoter sequences (Fig. 1a). Pvgf is a natural Vaccinia virus 
promoter controlling the abundant expression of VACV ORF C11R mRNA  
(YANG et al., 2015). 
 
Recombinant MVA expressing unmodified GFP served as a base-line 
vaccine. To achieve increased transport of GFP to cellular membranes, 
we added a myristoylation signal (MAURER-STROH et al., 2002; CHAN et 
al., 2011), and for nuclear localization we tagged the GFP with a specific 
nuclear localization signal (WANG et al., 1997) that translocates GFP to 
the cell nucleus (Fig. 1b). As a further control, recombinant virus MVA-
P7.5-GFP was used, encoding GFP under the transcriptional control of the 
natural VACV early-late promoter P7.5 (MACKETT et al., 1982), the first 
and probably still most widely used promoter for constructing recombinant 
Vaccinia viruses.  
IV. Results     29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Design of the recombinant MVAs.  
(a) Schematic diagram of the MVA genome containing the six major 
deletion sites (I to VI). The I8R-G1L site was used to insert GFP, myr-GFP 
or nls-GFP, under transcriptional control of the early Vaccinia virus 
promoter Pvgf  
(GTTTATATTACTGAATTAATAATATAAAATTCCCAATCTTGTCATAAA, 
underlined A indicates transcriptional start site +1 as described by Broyles 
and coworkers BROYLES et al., 1991). (b) Schematic representation of 
the MVA constructs with the nucleotide and amino acid signal sequences 
used to construct the different GFP variants. (c) Scheme of GFP 
localization within infected cells, with GFP represented by grey shading.  
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Our resulting recombinant MVA viruses should equally distribute GFP 
throughout the cell or deliver GFP predominantly to the cell nucleus (MVA-
nls-GFP) or cellular membranes (MVA-myr-GFP) (Fig. 1c). These viruses 
were purified and quality controlled according to standard procedures for 
generating recombinant MVA vaccines (KREMER et al., 2012b). During 
plaque purification, we analysed genetic integrity and stability by PCR 
using oligonucleotide primers to confirm MVA identity (PCR of the six 
major deletion sites of MVA in MVA-nls-GFP, MVA-myr-GFP and MVA-
GFP, MVA-P7.5-GFP) and correct insertion of GFP gene sequences 
within the MVA genome: MVA-nls-GFP, MVA-myr-GFP and MVA-GFP 
between the G1L and I8R genes, and MVA-P7.5-GFP insertion in deletion 
site III (Fig S1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1. Detection of genetic integrity and stability of the recombinant 
MVAs.  
(a) PCR of the six major deletion sites of MVA. (b) PCR of the I8R-G1L 
insertion site.  
 
To analyze growth behavior, we infected permissive DF-1 and non-
permissive MEF and NIH3T3 cells with the recombinant viruses and 
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collected cells and supernatants at the indicated times post-infection (Fig. 
S2). Titration by immunostaining was performed as described previously 
(KREMER et al., 2012b). The recombinant MVAs replicated efficiently in 
the avian cell line (DF-1), but not in cells of mammalian origin (MEF, 
NIH3T3) (Fig. S2). These findings confirmed the expected MVA 
phenotype, allowing handling of the recombinant viruses under biosafety 
level 1 conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S2. Recombinant MVA replication in cell lines.  
DF-1, MEF and NIH3T3 cells were infected at an m.o.i. of 0.01 for 
multistep growth analysis. Results are expressed as the average of three 
independent experiments. 
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Next we assessed the correct expression and predicted cellular 
localization of the GFPs by immunofluorescence microscopy of MVA-GFP-
infected cells (Fig. 2a). Infected DF-1 cells were fixed 24 h post infection 
and immunostained as described previously (BOULANGER et al., 2002) 
using primary anti-GFP (Life Technologies) and secondary Alexa Fluor 
488 antibody (Life Technologies). Cell nuclei were stained with DAPI 
(300 nM). As anticipated, we observed different patterns of green 
fluorescence, with varying cellular localizations depending on the MVA-
GFP construct. Serial optical sections showed that MVA-nls-GFP 
expressed protein was predominantly located within the cell nucleus. In 
contrast, MVA-myr-GFP expressed GFP that accumulated primarily on 
membranous structures, e.g. nuclear and cytoplasmic membranes, but 
was notably absent within the nucleus. MVA-GFP and MVA-P7.5-GFP 
rarely showed specific stained areas of green fluorescence, indicating 
equal distribution of GFP throughout the infected cell.  
 
To further analyze GFP synthesis, total cell lysates from infected CEF 
cells were analyzed by Western blotting using an anti-GFP rabbit antibody 
(Life Technologies; diluted 1:250) and a secondary anti-rabbit antibody 
(Cell Signaling Technology).  We compared GFP expression at 24 hours 
post-infection in DF-1 cells (Fig. 2b). β-actin-antibody (Thermo Scientific; 
1:500) was included to provide a loading control. Similar amounts of GFP 
were detected for all viruses tested. We also added cytosine arabinoside 
(AraC, 1 mg/ml) to the medium to inhibit viral DNA replication and 
synchronize all infections to strict early gene expression. As expected, the 
amounts of GFP produced by the control MVA-P7.5-GFP were clearly 
reduced compared with infection in the absence of AraC. In contrast, the 
addition of AraC increased the expression of GFP produced by MVA-GFP, 
MVA-myr-GFP and MVA-nls-GFP because of prolonged activity of viral 
early transcription.  
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Fig. 2. Characterization of recombinant GFP proteins.  
(a) Immunofluorescence staining of DF-1 cells infected with MVA viruses 
at an m.o.i. of 0.05 on cover slides and fixed 24 h post infection. Nuclei 
were stained with DAPI. Fluorescent images were captured with Keyence 
BZ-X710 at 100x magnification. (b) Western blot analysis of cell lysates 
prepared from DF-1 cells infected with MVA-GFP, MVA-nls-GFP, MVA-myr-
GFP and MVA-P7.5-GFP at an m.o.i of 5, with or without the addition of 
cytosine arabinoside (AraC), 24 hours post infection. 
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To assess the immunogenicity of these recombinant MVA-GFP candidate 
vaccines in vivo, we investigated the activation of GFP-specific CD8+ 
T cells in BALB/c mice. Groups of BALB/c mice were inoculated once (at 
day 1) or twice (at day 1 and 21) intramuscularly with 108 PFU of the MVA-
GFP constructs, or with corresponding amounts of phosphate-buffered 
saline (PBS) as a control (Fig. 3). Mice were sacrificed at day 8 or 28 and 
spleens were processed for enzyme-linked immunospot assays 
(ELISPOT) to detect interferon gamma (IFN-γ)-secreting CD8+ T cells. 
MVA-immunized mice induced significantly higher numbers of cells 
producing IFN-γ following GFP-specific peptide stimulation than mock-
inoculated control mice. Interestingly, after the second immunization at day 
21, MVA-myr-GFP induced significantly higher levels of GFP-specific 
CD8+ T cells than either MVA-GFP or MVA-nls-GFP. Notably, the levels of 
GFP-specific CD8+ T cells induced by infection with MVA-myr-GFP were 
similar to those seen after MVA-P7.5-GFP immunization. In addition, we 
monitored for MVA-specific CD8+ T cells and confirmed very comparable 
F226-34 peptide-specific (TSCHARKE et al., 2006) responses for all MVA-
based vaccines (Fig. 3c, d).  
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Fig. 3. Immunogenicity of recombinant MVA-GFP candidate vaccines. 
Groups of Balb/c mice (n=6) were immunized intramuscularly with 10
8 
PFU 
MVA or mock vaccinated (PBS, n=4). (a, c) At day 8 post vaccination, or 
(b, d) at day 28, following a boost at day 21, GFP-specific (a, b) or MVA 
F226-34-specific (c, d) IFNγ-producing CD8+T cells were measured using 
an ELISPOT kit (Mabtech) for mouse IFN-γ following the manufacturer’s 
instructions. The cells were stimulated with GFP200-208 peptide 
(HYLSTQSAL, 2 ng/ml, Thermo Fisher Scientific) or MVA F226-34 peptide 
(SPGAAGYDL, 2 ng/ml, Thermo Fisher Scientific) automated ELISPOT 
plate reader software (A.EL.VIS Eli.Scan software) was used to count and 
analyze the spots and differences between the groups were compared by 
t-tests using GraphPad Prism for Windows (GraphPad Prism Software, 
USA). Data are representative of two independent experiments. 
Statistically significant differences between the groups are shown as 
follows: *, P < 0.05; **, P < 0.01, ns, not significant. 
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Our aim was to generate an MVA vector vaccine that optimizes the 
induction of antigen-specific T cells. Recent data have increasingly 
highlighted the importance of antigen-specific T cells for generating 
protective immunity against infectious diseases, particularly in the context 
of more complex viruses such as influenza virus and human 
immunodeficiency virus, which characteristically mutate their antigenic 
structure very rapidly (BRANDLER et al., 2010; KREMER et al., 2012a). 
Moreover, long-lived memory CD8+ T cell immunity is considered 
important for cross-protection to ensure broader efficacy against different 
virus strains (BROWN & KELSO, 2009). Such vaccines are urgently 
needed to control pathogens with pandemic potential such as influenza 
(AHLERS & BELYAKOV, 2010).  
Previous studies have proposed cross-priming as the most important 
mechanism for antigen presentation upon primary immunization to induce 
efficient T cell response (GASTEIGER et al., 2007). Here, antigen-
presenting cells such as dendritic cells package the antigen expressed by 
donor cells using a major histocompatibility complex class I-molecule on 
their cell surface. 
We analysed whether localizing the antigen to different cellular sites could 
affect the T cell immunogenicity of recombinant MVA. For this purpose we 
constructed recombinant MVA expressing GFP or GFP linked to either a 
nuclear localization signal or a cell membrane-locating myristoyl group. 
Unmodified GFP delivered by MVA distributes equally throughout an 
infected cell and is not secreted, providing a good base line to analyse the 
influence of selected cell compartments. Our immunostaining results 
confirmed the accumulation of GFP to different subcellular localizations. 
Indeed, for this purpose GFP may be superior to other commonly used 
model proteins, such as ovalbumin, which is glycosylated in the 
endoplasmic reticulum/Golgi compartments and secreted from the cell 
(NORDER et al., 2010; BECKER et al., 2014). 
The choice of the early Pvgf promoter should not only drive early protein 
synthesis but also avoid the potential hiding of antigens in viral factories 
forming at late times of infection (KATSAFANAS & MOSS, 2007); both 
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parameters should facilitate efficient endogenous antigen presentation, 
which is needed to appropriately compare the different localization signals. 
Moreover, recent in vitro studies demonstrated the unique transcription 
strength of Pvgf (YANG et al., 2015), which additionally recommends the 
use of this promoter.  
The localization signals of the recombinant MVA-GFP viruses did not 
influence either their growth kinetics compared with non-recombinant 
wildtype virus or the expression levels of the modified antigens. Direct 
comparison of strict early expression induced by AraC treatment clearly 
indicated the much more efficient early gene expression by the Pvgf 
promoter compared with the well-established P7.5 promoter, as shown by 
GFP protein amounts detected in Western blot analysis. 
In vivo, we observed comparable activation levels of GFP epitope-specific 
CD8+ T cells for all vaccines after single immunization. However, after 
boost vaccination, expression of myristoylated GFP significantly enhanced 
the induction of GFP CD8+ T cells compared with the nuclear localization 
signal or unmodified GFP. These data are relevant because they confirm 
that GFP accumulation on cellular membranes has beneficial effects for 
activating antigen-specific CD8+ T cells. Moreover, these results support 
the hypothesis of Gasteiger suggesting that subcellular localization of 
target antigens could optimize the antigen characteristics to the 
requirements of the MVA vector system (GASTEIGER et al., 2007). 
Optimal interaction between the target antigen and the host cell system 
could then also result in enhanced cross-presentation and thereby induce 
an elevated immune response. Interestingly, early Pvgf in combination 
with myristoylation produced an immunization efficacy comparable to 
early-late P7.5-GFP. Pvgf is clearly the stronger early promoter, whereas 
the P7.5 promoter can be assumed to allow for higher levels of 
recombinant gene expression when combining early and late 
transcriptional activities (YANG et al., 2015). However, based on previous 
work (KASTENMULLER et al., 2007), we also expected a possible 
disadvantage of the early-late P7.5 promoter in boosting the CD8+ T cell 
response, which we did not observe. Thus, it could be that the late gene 
expression provided by P7.5 does contribute to the in vivo amplification of 
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GFP-specific CD8+ T cells. Subsequent studies will be necessary to 
investigate precisely the effect of myristoylation on antigen cross-
presentation and the activation of cytotoxic T cells in the context of MVA 
early-late gene expression. In addition, while myristoylation can be 
expected to enhance the immunogenicity of MVA-produced antigens 
similar to GFP, it will be interesting to further test other target proteins 
including glycosylated and membrane-anchored antigens.   
Taken together, our data support the idea that myristoylation could be a 
promising strategy for modifying antigens in the development of MVA-
based vaccines against threatening infectious diseases. The recombinant 
MVA-GFP-myr prototype that we developed here merits further analysis in 
the context of real antigens, for example the nucleoprotein antigen of 
influenza A virus. 
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V. DISCUSSION 
In spite of ongoing progress in medicine, there are still several infectious 
diseases especially threatening for public health. These diseases are 
either hard to treat or completely untreatable (such as HIV), show high 
pandemic potential (for example influenza) or can’t be prevented at all 
because of the lack of efficient vaccines. Therefore the development of 
novel vaccines including the investigation of innovative new vaccination 
strategies has high priority in medical research. Regarding the excellent 
safety profile and the results in preclinical as well as clinical trials, MVA 
serves as a promising platform in the development of vector vaccines. The 
objective in this study was to further enhance the cellular immunogenicity 
of recombinant MVA. For this purpose recombinant MVAs were 
constructed expressing green fluorescent protein as a model antigen 
under the transcriptional control of the strong poxvirus specific promoter 
Pvgf in combination with different subcellular localization signals. All 
constructed recombinant MVAs showed genetic stability and replicated 
efficiently in DF-1 cells. Moreover, the replication deficiency in mammalian 
cells confirmed safe handling of the recombinant MVA under biosafety 
level 1 conditions. The different MVA-GFP candidate vaccines efficiently 
produced green fluorescent protein and induced GFP-specific CD8+ 
T cells in vaccinated mice. In addition, combining GFP to a myristoylation 
signal statistically enhanced the cellular immunogenicity of GFP. Thus, 
myristoylation could serve as a promising tool to modify recombinant MVA 
expressing target proteins of various infectious diseases.  
Why does development of vaccines still have high priority in medical 
research? 
Today, infectious diseases yearly cause about 10 million deaths worldwide 
despite an obvious decrease through medical progress compared to data 
published about ten years ago (MORENS et al., 2004). Thus, infectious 
diseases still amount to about 17% of the annual 56 million deaths in the 
world in 2012 and represent one of the main problems in public health 
(figure 5). Children in developing countries are mainly affected 
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(GUERRANT & BLACKWOOD, 1999). Figure 5 shows the leading causes 
of death worldwide and highlights the major infectious diseases. The figure 
excludes deaths through complications or consequences of past or 
chronic infections to allow comparison with previous studies (MORENS et 
al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Leading causes of death worldwide in 2012  
(Data published by World Health Organization 2014 (WHO methods and 
data sources for country-level causes of death 2000-2012);  
http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.
html) 
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According to the data published in 2014 by the WHO respiratory infections 
including influenza, HIV, tuberculosis and malaria are besides the 
diarrhoeal diseases the most lethal infectious diseases. Unfortunately, the 
development of an efficient and safe vaccine against HIV has so far not 
been successful. Furthermore today no universal influenza vaccine is 
available which would be needed to efficiently protect against all influenza 
viruses including novel subtypes with pandemic potential. These more 
complex diseases are known to require cellular immune responses for 
protection (PANTALEO & KOUP, 2004; HOFT, 2008; ALTENBURG et al., 
2014). For this reason it is important to focus not only on the induction of 
antibodies, but also on the strong activation of T cells in the development 
of new vaccines. Generally, the development of vaccines efficient against 
complex infectious diseases has high priority in medical research because 
vaccination is regarded to be the most effective and cost-efficient 
prevention method (SALLUSTO et al., 2010; PULENDRAN & AHMED, 
2011).  
Factors with potential influence on T cell immunity triggered by MVA 
The activation of the cellular immune system does not only lead to the 
generation of effector and memory T cells. It furthermore also supports the 
B cell response (WEBER et al., 2009). Enhanced B cell response results 
in antibody production and supports the efficacy of the vaccine as well. 
Many different factors for the design of poxvirus vectors are considered to 
have positive effects on the activation of the humoral immune system. 
These factors can either modify the vector backbone or the target antigen. 
The induction of T lymphocytes can for example be influenced through the 
amount of target protein delivered. It is known that the amount of 
heterologous protein clearly correlates with the immune response of 
vaccinated mice (WYATT et al., 2008; GARCIA-ARRIAZA & ESTEBAN, 
2014). These data suggest that recombinant MVA should produce the 
highest amount of protein which is possible without affecting the stability 
and growth behavior of the virus (WYATT et al., 2008). High production 
levels of protein can mainly be achieved through the use of strong and 
efficient promoters. For this reason numerous experimental studies 
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consistently investigate and compare natural poxvirus-specific promoters 
as well as new synthetic promoters for their efficacy and strength (for 
example BAUR et al., 2010; BECKER et al., 2014; YANG et al., 2015). It is 
remarkable that in poxvirus vector systems additionally to the expression 
strength of the target antigen also the expression time during the life cycle 
of the virus can be specifically chosen. The expression time is even 
considered to be crucial for the type of the immune response (activation of 
CD4+ or CD8+ T cells). CD4+ T cells mainly recognize late antigens, 
whereas activation of cytotoxic T cells is predominantly associated with 
early expression (MOUTAFTSI et al., 2007; YANG et al., 2011; GARCIA-
ARRIAZA & ESTEBAN, 2014). Today strong and well-characterized early, 
early-late as well as late promoters for the MVA system are available. 
These different promoters have specific advantages and disadvantages 
depending on the experimental approach and setting. Early-late 
expression allows antigen expression during the whole life cycle of MVA. 
In contrast, the use of late promoters only leads to antigen expression 
during the late cycle phase. Furthermore it can be associated with hiding 
of antigen in viral factories which are formed at later times of MVA 
infections (KATSAFANAS & MOSS, 2007). For this reason early 
promoters are considered to be better suitable for efficient induction of the 
endogenous pathway. Thus, early promoters are usually used in studies 
which aim at investigating T cell responses (BAUR et al., 2010). Apart 
from the promoter strength the spacer length also seems to play an 
important role. 2015 a study firstly confirmed the positive effect of an 
increased promoter spacer length on the activation of T lymphocytes (DI 
PILATO et al., 2015). 
Another strategy for the improvement of the cellular immune response 
experienced over the last years consists in co-expression of different 
molecules. In this context, it is a good approach to combine different 
antigens of the same target virus. The combination of specific T cell 
antigens with antigens which induce strong antibody production should 
allow to efficiently activate both, the humoral immune system and the 
cellular immune system. Furthermore it is also possible to combine 
antigens of different viral subtypes for the induction of cross-protective 
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immunity. This could especially be supportive in the development of 
influenza vaccines. Besides the co-expression of different antigens, 
another promising approach is to combine target antigen with co-
stimulatory molecules such as cytokines. Co-delivery of cytokines under 
the control of poxvirus specific promoters or exogenous inoculation can 
result in enhanced activation and recruitment of immune cells (GARCIA-
ARRIAZA & ESTEBAN, 2014). IL-2 (BERTLEY et al., 2004), IL-12 
(ABAITUA et al., 2006), IFNγ (ABAITUA et al., 2006) or GM-CSF 
(CHAVAN et al., 2006) have amongst other cytokines successfully been 
used in the MVA vector system. In general, for the construction of 
recombinant vectors co-expressing several proteins, the insertion of larger 
DNA sequences is required. In this context MVA serves as an appropriate 
vector because of its large genome and high genetic plasticity. 
Next, the immune response could be improved through the combination of 
different vaccines in prime-boost vaccination protocols (for review see 
GARCIA-ARRIAZA & ESTEBAN, 2014). Today, poxvirus vectors 
combined with other vaccines are commonly used in preclinical and 
clinical trials. Here, the poxvirus vector can be used as the priming vaccine 
as well as the booster component. Recombinant MVAs have so far 
successfully been used in several experimental studies combined with 
DNA vectors (GOMEZ et al., 2007), recombinant influenza viruses 
(GONZALEZ-ASEGUINOLAZA et al., 2003), adenoviruses (REYES-
SANDOVAL et al., 2010; RATTO-KIM et al., 2012) or other poxvirus 
vectors (SANTRA et al., 2007). Results from these data clearly 
recommend further investigation and use of heterologous prime-boost 
vaccination strategies. 
Additionally to the improvement of the vector backbone described above 
another approach is to optimize the target antigen. In this context the 
choice and suitable design of the target antigen certainly plays the key 
role. Optimal adjustment of the antigen to the specific requirements of the 
delivering vector system is essential to efficiently activate the immune 
system (GASTEIGER et al., 2007). Data published recently also highlight 
the importance of long-lived antigen for the induction of the cellular 
immune response. It is generally supposed that long-lived antigen could 
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enhance the cross-presentation pathway and therefore induce a stronger 
activation of cytotoxic T cells (GASTEIGER et al., 2007). Furthermore the 
antigen chosen should preferably have full length instead of being 
shortened. Full length antigen can support immune reaction not only 
against a single, but potentially also against multiple T cell epitopes 
(GASTEIGER et al., 2007). In this context we should keep in mind that 
basically only 2% of all peptide fragments which are generated through 
processing of foreign proteins within the cell have an amino acid structure 
which can bind to MHC and is consequently able to activate T cells 
(WEBER et al., 2009).  
Data published recently including this study also consider effects of the 
target protein’s localization on the immunogenicity of recombinant MVA 
(GASTEIGER et al., 2007). Target protein can generally be expressed all 
over an infected cell or it can be located in a specific subcellular 
compartment. Distinct subcellular localizations can be achieved through 
the use of cellular localization signals. But on the other hand it is also 
possible to abrogate the natural subcellular distribution of a target antigen 
through removing its own localization signal. The purpose of such 
modifications is to improve the accessibility of target protein to the cellular 
apparatus processing protein. Generally, enhanced protein depletion and 
presentation of antigenic material obviously seem to support the activation 
of T lymphocytes. 
Another parameter which is discussed for further enhancement of 
recombinant MVA’s immunogenicity is the use of adjuvants. Adjuvants are 
commonly used in many vaccines currently available. The major task of 
adjuvants is to enhance the efficacy of vaccines by triggering rapid, strong 
and long-lasting immune responses (GUPTA & SIBER, 1995). Moreover 
adjuvants are also able to selectively modulate immune responses to 
MHC class I or MHC class II molecules. This could be helpful in the control 
of diseases caused by intracellular pathogens (GUPTA & SIBER, 1995). In 
addition, adjuvants containing synthetic T cell epitopes have already been 
developed which can specifically enhance the cellular immunogenicity 
(HADDEN, 1994).  However, the use of adjuvants in the MVA vector 
system is controversially discussed for good reasons. On the one hand 
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adjuvants indeed enhance the immunogenicity of many vaccines available 
and could therefore also be useful in the MVA vector system. But on the 
other hand previous work clearly considers adjuvants as dispensable for 
most MVA based vaccines because of the intrinsic immunogenicity of the 
vector (ALTENBURG et al., 2014). Furthermore the use of adjuvants in 
vaccines is generally discussed. Many adjuvants are known to have great 
toxic potential and can induce adverse and severe side effects following 
vaccination (GUPTA & SIBER, 1995). For this reason the dispensability of 
adjuvants is considered to be one important factor which supports the 
generation of safer vaccines. Therefore MVA renouncing the addition of 
adjuvants serves as a promising vaccine platform. 
Importance of T cell response for efficacy of MVA based vaccines 
Today it is consensus that protective vaccines against more complex 
diseases such as HIV, tuberculosis or malaria require both, induction of 
strong T cell immunity and efficient activation of the humoral immune 
system. Especially vaccines against HIV lack a coordinated B and T cell 
response (GOMEZ et al., 2011; GOMEZ et al., 2012) because 
T lymphocytes are crucial for the control of viremia during acute infections 
(McELRATH & HAYNES, 2010). Additionally a large population-based 
study generally provides evidence that Gag-specific T cell responses can 
efficiently control chronic infections and are affiliated with lower viral loads 
(KIEPIELA et al., 2007; McELRATH & HAYNES, 2010). Several 
recombinant MVA vaccines expressing Gag have already been tested for 
their potential to induce cellular immune responses (for review see 
GOMEZ et al., 2012). The results of these studies clearly indicate MVA as 
a promising Gag vector for combined induction of the cellular immune 
system and the humoral immune system.  
In case of malaria, T cell activation is also required for the protective 
efficacy of vaccines because inducing protective immunity against 
sporozoites only through humoral immune responses is obviously 
challenging (HILL et al., 2010). Several animal studies and human clinical 
trials have confirmed the key role of cytotoxic T cells in the elimination of 
the parasites (DOOLAN & HOFFMAN, 2000; DE BARRA et al., 2014). In 
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general, protection against malaria is clearly related to high levels of CD8+ 
T cells (SCHNEIDER et al., 1998; DE BARRA et al., 2014). Moreover, 
cytotoxic T cell immunity even seems to be the vital factor for prevention of 
parasitemia and clearance of all parasites (EWER et al., 2015). For this 
reason malaria vaccine development is focused on the generation of 
vaccines which can activate both, B cells and T lymphocytes.  
The currently available tuberculosis vaccine, Bacille Calmette-Guérin 
(BCG), is commonly used especially in developing countries (BROOKES 
et al., 2008). However, a meta-analysis published in 1994 reports that 
BCG generally only reduces the risk of tuberculosis by 50% (COLDITZ et 
al., 1994). It efficiently protects children from tuberculous meningitis, but 
the efficiency against pulmonary tuberculosis shows an inappropriately 
high variability (COLDITZ et al., 1994; TRUNZ et al., 2006; BROOKES et 
al., 2008). Therefore the development of new tuberculosis vaccines is still 
ongoing. Experimental studies indicate the important role of cytotoxic 
T cells for the induction of protective immunity in mice (FLYNN et al., 
1992). In this context, a MVA vaccine expressing 85A antigen has been 
developed. This vaccine indeed induced 85A-specific T cells, when tested 
on volunteers in Africa (BROOKES et al., 2008) and proved to be well 
tolerated when tested in a large phase 2b trial in about 1,400 infants 
(TAMERIS et al., 2013). These data showed that the 85A antigen alone 
may not be sufficient to provide protective immunity, but the safety data 
clearly recommend further development of tuberculosis vaccines on the 
basis of MVA. 
Even if it is often underlined that T cell based immunity through 
vaccination with recombinant MVA is not able to completely prevent an 
infection alone, it indeed can trigger rapid protection. In this context the 
general rapid activation of T cells which can of course also be achieved in 
the MVA vector system is especially vital. T cell responses usually only 
need about four days to develop. In contrast antibody production takes 
obviously longer with approximately eight to ten days (MURPHY et al., 
2008). So even if the T cell immunity is not able to prevent the infection 
and the disease following, the rapid response can play the key role in the 
prophylaxis of infectious diseases such as influenza. This point has been 
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confirmed in recent studies which investigated MVA’s potential to induce 
short term protection using ectromelia virus (ECTV) challenge infections in 
mice (KREMER et al., 2012a; VOLZ et al., 2014). ECTV, the causative 
agent of mousepox, is probably the best animal model available for human 
smallpox infections. The results clearly show that the early protective 
capacity of MVA depends on the induction of CD4+ and CD8+ T cells. 
Here, MVA-specific T cells could already be detected at day two, whereas 
the number of MVA-specific antibodies didn’t start to increase until day 
eight. These studies furthermore show the adequacy of low-dose 
immunization and consider the dispensability of the humoral immune 
response for rapid protection.  
Activation of CD8+ T cells has recently also been confirmed in 
experimental studies with a recombinant MVA vaccine delivering spike 
glycoprotein of Middle East respiratory syndrome coronavirus (MERS-
CoV) (SONG et al., 2013; VOLZ et al., 2015). MERS is a zoonotic 
infectious disease which has its natural reservoir in camels. It has caused 
severe human respiratory diseases in Middle Eastern countries since 
2012. The MERS triggered respiratory syndrome is reported to result in 
death of about 20% to 40% of those infected (MACKAY & ARDEN, 2015). 
In 2015 the MVA-MERS-CoV vaccine was also successfully tested in a 
challenge experiment using dromedary camels (HAAGMANS et al., 2016). 
The success of this vaccination is hypothesized to be based on the 
induction of MERS-CoV neutralizing antibodies. However, the potential 
contribution of vaccine induced CD8+ and/or CD4+ T cells to protective 
immunity is not known and warrants further investigation. Generally, the 
development of camel-specific MERS-vaccines is very vital for the 
protection of humans who work in close contact with the animals.  
Furthermore the protective efficacy of recombinant MVA expressing 
nucleoprotein of influenza also indicates the importance of T cell activation 
in the MVA vector system. As previously mentioned, nucleoprotein is able 
to efficiently induce T cells. Previous immunization experiments using 
recombinant MVA delivering nucleoprotein highlight that protective 
immunity against lethal challenge with influenza virus is affiliated with high 
CD4+ and CD8+ T cell responses (HESSEL et al., 2014). These data also 
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confirm that pre-existing CD4+ T cell responses obviously correlate with 
protection even without influenza specific antibodies (WILKINSON et al., 
2012; HESSEL et al., 2014). The efficacy of a T cell-based MVA influenza 
vaccine expressing nucleoprotein and matrixprotein 1 has also been 
demonstrated in a phase 2a influenza challenge study published recently 
(LILLIE et al., 2012).  
The exact mechanism of short term protection triggered by T cells is still 
subject of present research. However, it is supposed that rapid T cell 
immunity could probably bypass the time until the infection leads to the 
additional and long-lasting protective antibody response. This approach is 
basically also regarded as progressively important for the prevention of 
new threatening infections such as Ebola or MERS corona virus.   
Role of T cells in MVA-based cancer immunotherapies 
However, T cells are not only important for the protective capacity of 
vaccines against infectious diseases. They are also considered to play a 
key role in the development of efficient new cancer therapies. Here, T cells 
could be determining factors for the efficacy of vaccines on the basis of 
tumor-associated antigens. Such vaccines are especially promising in the 
control of immunogenic tumors like melanomas. Spontaneous regression 
of melanomas is obviously associated with infiltration of T cells (LOWES et 
al., 1997). Therefore research investigates more and more tumor-
associated target antigens for their potential to induce tumor-specific T cell 
responses. 
In this context, tyrosinase serves as a promising tumor-associated target 
antigen for cancer immunotherapies because it is regularly expressed in 
melanomas (CHEN et al., 1995). Its natural function is being the key 
enzyme of the melanin biosynthesis. Expressed by MVA, this enzyme is 
able to efficiently trigger tyrosinase- and melanoma-specific cytotoxic 
T cell responses in vitro and in vivo (DREXLER et al., 1999). In a phase I 
clinical study melanoma patients were treated with dendritic cells which 
had been infected with recombinant MVA delivering tyrosinase (DI 
NICOLA et al., 2003). In general, this treatment was well tolerated and 
V. Discussion      49 
triggered tyrosinase-specific T cells in vivo (DI NICOLA et al., 2004). Apart 
from tyrosinase, tyrosinase-related-protein-2 (TRP-2) also serves as an 
appropriate target antigen for T cell based cancer therapy. It is remarkable 
that the expression of TRP-2 even seems to correlate with the resistance 
of melanoma cells against radio- and chemotherapy (PAK et al., 2004). 
TRP-2 delivered by recombinant MVA can efficiently be recognized by 
dendritic cells and therefore also activate T lymphocytes (PASCHEN et al., 
2005).  
However, melanoma is not the only type of cancer which responds 
positively on T cell based immunotherapies. In approximately 30% human 
breast cancer is associated with the overexpression of human epidermal 
growth factor receptor-2 (HER-2/neu) (SLAMON et al., 1989). This 
overexpression has also been demonstrated in ovarian and renal cancer 
(SLAMON et al., 1989). HER-2/neu is a proto-oncogenic glycoprotein 
which belongs to the tyrosinase-kinase receptors family (COUSSENS et 
al., 1985). Overexpression of HER-2/neu is related to a down-regulation of 
MHC class I molecules and disturbance of CD8+ T cell mediated cell lysis 
(HERRMANN et al., 2004). The down-regulation of MHC-class I molecules 
can result in further tumor progression (HERRMANN et al., 2004). For this 
reason it seems to be a promising approach to use HER-2/neu as a tumor-
associated antigen and recombinant MVA has been used for efficient 
delivery of HER-2/neu antigen to human dendritic cells (KASTENMULLER 
et al., 2006).  
Future perspectives 
Today safe and highly effective viral vectors on the basis of the well-
characterized MVA are commonly generated. Further preclinical as well as 
clinical studies are essential to define the recombinant MVAs which are 
able to fully protect against specific diseases. Thus, further enhancement 
of the cellular immune response certainly plays an important role, 
especially in the development of vaccines against complex infectious 
diseases. In general, recombinant MVAs are also suitable candidates for 
the development of cancer immunotherapies. In this context, the 
combination of MVA with further innovative treatment tools such as the 
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simultaneous use of checkpoint inhibitors seems to be a very promising 
approach for future research.  
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VI. SUMMARY 
Improving the cellular immunogenicity of recombinant Modified 
Vaccinia virus Ankara using green fluorescent protein as model 
system 
Infectious diseases are still threatening for public health and cause about 
17% of the annual deaths worldwide despite great medical progress over 
the last decades. In this context more complex diseases such as 
influenza, HIV, tuberculosis or malaria are especially problematic. These 
infectious diseases are characterized either by being untreatable or 
unpreventable because of the lack of efficient vaccines. 
The development of vaccines has for a long period of time predominantly 
been based on the induction of humoral immune responses. But today the 
cellular immune system is also considered to play an important role in the 
prevention of more complex diseases. So the focus of vaccine 
development is changing more and more. In this context, Modified 
Vaccinia virus Ankara (MVA) serves as a promising platform for vaccine 
development because it is able to induce both, humoral immune 
responses and cellular immune responses. MVA is a safety tested, 
replication deficient poxvirus vector which can stably express heterologous 
proteins. Apart from being used as recombinant vector vaccine, MVA also 
serves as a promising tool in the development of cancer immunotherapies 
which are based on the induction of T cells.  
In this study we investigated an innovative antigen modification tool for its 
potential to further enhance the cellular immunogenicity of recombinant 
MVA. For this purpose we introduced green fluorescent protein (GFP) in 
combination with different localization signals to the MVA genome. GFP 
was tacked either to myristoyl acid or to a nuclear localization signal and 
compared with unmodified GFP. The genetic integrity and stability of the 
recombinant MVAs was confirmed via polymerase chain reaction (PCR). 
Moreover, growth kinetics of the candidate viruses in DF-1, MEF and 
NIH3T3 cells showed the replication deficiency of the generated MVAs in 
mammalian cells. The stable expression of the GFP variants was verified 
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using immunoblot analysis. Furthermore, microscopical analysis confirmed 
the expected specific subcellular localization sites of GFP triggered 
through the different localization signals. All MVA-GFP candidate vaccines 
induced GFP-specific CD8+ T cells after intramuscular inoculation of 
BALB/c mice. However, after boost vaccination modification by 
myristoylation signal resulted in an increased level of antigen-specific 
CD8+ T cells statistically significant compared to unmodified GFP or to 
nuclear localized GFP. Therefore the addition of myristoylation 
successfully enhanced the cellular immunogenicity of the recombinant 
MVA. Generally, this result supports the further use of myristoylation as 
promising modification tool for the generation of MVA based vaccines 
delivering specific antigens of infectious diseases.  
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VII. ZUSAMMENFASSUNG 
Verbesserung der zellulären Immunogenität von rekombinantem 
Modifizierten Vaccinia Virus Ankara unter Verwendung von Grün 
fluoreszierendem Protein als Modellsystem 
Trotz des großen medizinischen Fortschritts während der letzten 
Jahrzehnte stellen Infektionskrankheiten eine nicht zu unterschätzende 
Bedrohung für das öffentliche Gesundheitswesen dar. 
Infektionskrankheiten zählen mit einem Anteil von 17% an den jährlich 
weltweit registrierten Todesfällen immer noch zu den 
Haupttodesursachen. Dabei gelten vor allem komplexere Infektionen wie 
Influenza, HIV, Tuberkulose oder Malaria als besonders problematisch. 
Diese Infektionskrankheiten weisen häufig einen schweren Verlauf auf 
oder sind nicht heilbar. Aufgrund des Fehlens wirksamer und sicherer 
Impfstoffe ist zudem die Prävention dieser Krankheiten nur eingeschränkt 
oder überhaupt nicht möglich.  
Die Entwicklung neuer Impfstoffe basierte lange Zeit hauptsächlich auf der 
Induktion des humoralen Immunsystems. Inzwischen rückt aber auch die 
Aktivierung des zellulären Immunsystems immer mehr in den Fokus, da 
viele neuere Forschungsarbeiten in effizienten T-Zell-Antworten den 
Schlüssel für die Prävention komplexerer Infektionskrankheiten sehen. In 
diesem Zusammenhang dient Modifiziertes Vacciniavirus Ankara (MVA) 
als eine vielversprechende Plattform für die Impfstoffentwicklung, denn 
MVA kann sowohl die Aktivierung des humoralen als auch des zellulären 
Immunsystems induzieren. Das Pockenvirus MVA kann stabil Fremdgene 
exprimieren und dient somit als viraler Vektor in der Impfstoffentwicklung. 
Da MVA in menschlichen Zellen und Säugetierzellen nicht replizieren 
kann, gilt die Verwendung dieses Vektors als besonders sicher. Außer in 
der Impfstoffentwicklung wird MVA auch in der Entwicklung von neuen 
Krebstherapien, die auf der Induktion von T-Zellen basieren, eingesetzt.  
Im Rahmen dieser Arbeit wurde eine neue Methode zur Modifizierung von 
Proteinen auf ihre Immunogenität im MVA Vektorsystem getestet. Dazu 
wurden Gensequenzen für Grün fluoreszierendes Protein (GFP) in 
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Kombination mit unterschiedlichen Lokalisierungssignalen in das MVA 
Genom integriert. GFP wurde dabei entweder mit einer Myristoylierungs- 
oder einer nukleären Lokalisierungssequenz versehen und mit 
unmodifiziertem GFP verglichen. Die genetische Stabilität der 
rekombinanten MVAs  wurde mittels Polymerase-Ketten-Reaktion 
nachgewiesen. Wachstumskurven auf DF-1, MEF und NIH3T3 Zellen 
bestätigten sowohl die funktionierende Replikation in Zellen aviären 
Ursprungs als auch die fehlende Vermehrungsfähigkeit der rekombinanten 
Viren in Säugetierzellen. Zudem wurde die stabile Expression der 
verschiedenen GFP-Varianten mithilfe von Immunfluoreszenz-Analysen 
gezeigt. Die erhoffte subzelluläre Lokalisation von GFP in Abhängigkeit 
von den eingesetzten Lokalisierungssequenzen wurde mittels 
Fluoreszenzmikroskopie bestätigt. Im Tierversuch konnten alle 
rekombinanten MVA nach intramuskulärer Injektion die Aktivität GFP-
spezifischer zytotoxischer T-Zellen induzieren. Nach der zweiten 
Immunisierung war die Aktivität der CD8+ T-Zellen, induziert durch 
myristoyliertes GFP, signifikant erhöht im Vergleich zu den weiteren GFP 
Varianten. Die hier untersuchte Myristoylierung konnte somit erfolgreich 
die zelluläre Immunogenität des rekombinanten MVA steigern. 
Myristoylierung empfiehlt sich deshalb auch als zukunftsträchtige Methode 
zur Modifizierung weiterer Antigene  im MVA Vektorsystem.  
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IX. ABBREVIATIONS 
 
ABC ATB-binding cassette family 
AIDS Acquired immunodeficiency syndrome 
AMA1 Apical membrane antigen 1 
APC Antigen-presenting cell 
ATP Adenosine triphosphate 
BALB/c Albino, laboratory bred strain of house mouse 
BCG Bacille Calmette-Guérin 
CD4 Cluster of differentiation 4 
CD8 Cluster of differentiation 8 
CEF Chicken embryo fibroblasts 
CVA Chorioallantois Vaccinia virus Ankara 
DAPI 4’,6-Diamidin-2-phenylindol 
DF-1 Chicken embryo fibroblast cell line prepared by Doug 
Foster (University of Minnesota) 
 
DNA Desoxyribonucleic acid 
ECTV Ectromelia virus 
ELISPOT Enzyme-linked immuno spot assay 
ENF HIV gene encoding for envelope proteins 
EV Enveloped virion 
GAG HIV gene encoding for proteins of matrix and capside 
GFP Green fluorescent protein 
GM1 Monosialotetrahexosylganglioside 1 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
HA Hemagglutinin 
HBV-S Hepatits B virus surface protein 
HER-2/neu Human epidermal growth factor receptor 2 
HIV Human immunodeficiency virus 
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hpi Hours post infection 
IAV Influenza A virus 
IL Interleukin 
INF Interferon 
Kb Kilobase 
kDa Kilodalton 
LMU Ludwig-Maximilians-Universität München 
M1 Matrixprotein1 
MEF Mouse embryonic fibroblasts 
MERS-CoV Middle East respiratory syndrome coronavirus 
ME-TRAP Thrombospondin related adhesive protein fused to a 
multi-epitope 
 
mg Milligram 
MHC Major histocompatibility complex 
ml Milliliter 
MOI Multiplicity of infection 
mRNA Messenger ribonucleic acid 
MTB Mycobacterium tuberculosis bacteria 
MV Mature virion 
MVA Modified Vaccinia virus Ankara 
NA Neuraminidase 
NEF Negative factor 
ng Nanogram 
NIH3T3 Mouse embryonic fibroblast cell line derived from 
albino mice from the National Institutes of Health, 
Bethesda 
 
nM Nanomolar 
NP Nucleoprotein 
ORF Origin of replication 
OVA Ovalbumin 
PAMP Pathogen associated molecular pattern 
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PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
P. falcip Plasmodium falciparum 
POL HIV gene encoding viral enzymes 
PRR Pattern recognition receptor 
RNA Ribonucleic acid 
TAP Transporters associated with antigen processing 
TRP Tyrosinase-related-protein 
WHO World Health Organization 
WT Wildtype 
VACV Vaccinia virus 
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